AstraZeneca to buy Amolyt Pharma for US$1.05 billion to boost rare-disease portfolio
DRUGMAKER AstraZeneca said on Thursday (Mar 14) it would acquire rare endocrine diseases-focused firm Amolyt Pharma for US$1.05 billion in ...
Tag: raredisease
Forbes 40under40 stands as a distinguished platform revered for its commitment to honoring and applauding the remarkable achievements of exceptional individuals who have yet to reach the age of 40. This esteemed initiative serves as a beacon of inspiration, spotlighting trailblazers across various industries and domains, showcasing their innovation, leadership, and impact on a global scale.
© 2025 Forbes 40under40. All Rights Reserved.